Attached files
file | filename |
---|---|
8-K - FORM 8-K - MATRIXX INITIATIVES INC | p18380e8vk.htm |
EX-2.2 - EXHIBIT 2.2 - MATRIXX INITIATIVES INC | p18380exv2w2.htm |
EX-2.1 - EX-2.1 - MATRIXX INITIATIVES INC | p18380exv2w1.htm |
EX-4.1 - EX-4.1 - MATRIXX INITIATIVES INC | p18380exv4w1.htm |
EX-99.1 - EX-99.1 - MATRIXX INITIATIVES INC | p18380exv99w1.htm |
Exhibit 99.2
Matrixx Initiatives, Inc. Enters Settlement Agreement to Resolve Nationwide Personal Injury
Litigation
Litigation
Scottsdale, AZ December 14, 2010; Matrixx Initiatives, Inc. (Nasdaq: MTXX) and Lead Plaintiffs
Counsel in the Federal Multi-District Litigation in the District of Arizona and the consolidated
proceedings pending in state courts in California and Arizona, Charles S. Zimmerman, Steven Skikos,
and Stephen Leshner, respectively, today announced the parties to product liability suits against
Matrixx Initiatives, Inc. and Zicam LLC pending nationwide have reached agreement to resolve the
bulk of outstanding cases and claims on mutually satisfactory terms. Under the settlement
agreement, approximately 1,014 plaintiffs and 1,127 claimants who allege loss of smell and/or taste
arising out of their use of Zicam Cold Remedy and other products will be eligible to participate in
a voluntary Settlement Program. In return, plaintiffs and claimants will dismiss or release their
cases with prejudice. The Company will pay a total of $15.5 million, including $11.5 million after
satisfaction of certain contingencies and approximately $4 million in subsequent payments within
twenty-one months. Any claims made after the date of the settlement agreement will not be eligible
to participate in the Settlement Program.
About Matrixx Initiatives, Inc.
Matrixx Initiatives, Inc. is an over-the-counter healthcare company that develops and
markets Zicam® products. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products
in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam
Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well
as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx
products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq:
MTXX), visit our website at www.matrixxinc.com. For additional information, contact
William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Vice President
of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale,
Arizona 85255.